| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/03/2003 | US20030125330 Anxiolytics and antidepressants |
| 07/03/2003 | US20030125327 Prodrugs of imidazopyridine derivatives |
| 07/03/2003 | US20030125326 Farnesyl protein transferase inhibitor combinations |
| 07/03/2003 | US20030125324 Alpha 4 beta 1 integrin and CD49d/ CD29 (vla-4); antiinflammatory agents |
| 07/03/2003 | US20030125323 Use of selective potassium channel openers |
| 07/03/2003 | US20030125322 Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine |
| 07/03/2003 | US20030125321 Administering a compound that inhibits the contraction of the myosin light chain of pulmonary epithelial cells |
| 07/03/2003 | US20030125320 Seratonin reuptake inhibitors potently binding to the 5-HT1A receptor, dopaminergic agents; antidepressants, psychosis, anxiolytic and antiischemic agents; panic order; obsessive compulsive disorder, impulse control disorder, alcohol abuse |
| 07/03/2003 | US20030125319 Administering an estrogen agonist/ antagonist while reducing the side effects associated with estrogen administration; urinary and vaginal infections; incontinence; vaginal dryness; kits for assessing vaginal health |
| 07/03/2003 | US20030125318 Benzothiazole derivatives with activity as adenosine receptor ligands |
| 07/03/2003 | US20030125317 Vitronectin receptor antagonists |
| 07/03/2003 | US20030125316 Cardiovascular disorders including atherosclerosis and other coronary artery disease; anticholesterol agents; antilipemia agents; nontoxic; prophylactic; e.g., 2,3,4,5-tetrahydro-1-benzothiepine 1,1-dioxide and nicotinic acid or nigeritrol |
| 07/03/2003 | US20030125315 Providing a focused approach that permits a more rapid screening of probes with potential for association with a particular binding site with a higher likelihood of success; combinatorial chemistry; screening; computer software |
| 07/03/2003 | US20030125313 Prophylaxis/treatment of respiratory system disorders; administered by inhalation; potentiation; reversible airways obstruction, e.g., asthma, chronic obstructive pulmonary diseases (COPD) (e.g. bronchitis, emphysema); infections |
| 07/03/2003 | US20030125312 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation- related cardiovascular disorders |
| 07/03/2003 | US20030125311 Steroid hormones and nontoxic compounds, e.g., Taxol (able to cross the blood-brain barrier) replace pregnenolone bound to microtubule-associated proteins to aid in assembling and stabilizing of microtubules; nervous, glandular disorders |
| 07/03/2003 | US20030125310 Combine solutions of each vitamin, i.e, K, D's, E and A, in water or an inert oil and emulsify using a protective colloid; drying; fineness; discoloration inhibition; homogeneity; oxidation resistance |
| 07/03/2003 | US20030125309 Cyclic ether vitamin D3 compounds, 1alpha(OH) 3-epi- vitamin D3 compounds and uses thereof |
| 07/03/2003 | US20030125308 Antipruritic agents for external use |
| 07/03/2003 | US20030125307 Transdermally administering a preparation containing only acetylsalicylic acid as an active ingredient; bronchial asthma, allergic rhinitis, atopic dermatitis; eczema, lichen Vidal; insect stings; pruritis; side effect reduction |
| 07/03/2003 | US20030125306 N-methyl-6-phenyl-3,5-hexadienoylhydroxamic acid as an example; gene expression inhibition; antitumor and -carcinogenic agents; blood disorders (hemoglobinopathies); genetic disorders/metabolic disorders (cystic fibrosis) |
| 07/03/2003 | US20030125305 Treating patients who have become resistant to a Brc-Abl tyrosine kinase inhibitor, e.g., imatinib mesylate, with a nucleoside analog of a 2-cytosinyl-1,3-dioxolane; chronic myelogenous leukemia in blastic phase; anticarcinogenic agents |
| 07/03/2003 | US20030125304 Substituted amino ketone compounds |
| 07/03/2003 | US20030125303 Transdermal formulation for repair and maintenance of connective tissue |
| 07/03/2003 | US20030125302 Folic acid-polysaccharide complex, its preparation method and pharmaceutical composition containing the same as active component |
| 07/03/2003 | US20030125299 Method for treating or preventing inflammatory diseases |
| 07/03/2003 | US20030125297 Method of hiv and hpv prophylaxis |
| 07/03/2003 | US20030125287 Antisense oligonucleotides and methods to induce tumor cell death |
| 07/03/2003 | US20030125286 Transcriptional silencer protein NRF |
| 07/03/2003 | US20030125284 Agents that modulate DNA-PK activity and methods of use thereof |
| 07/03/2003 | US20030125281 Compositions and processes using siRNA, amphipathic compounds and polycations |
| 07/03/2003 | US20030125268 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 07/03/2003 | US20030125267 A bicyclic heteroaromatic compound containing two keto, two ester, a carbamate groups and a methyl, hydroxy and amine substituted oxypyran ring; useful antibacterial agent for treating pneumonia, skin, soft tissue and bone infections |
| 07/03/2003 | US20030125266 Administering a 14 membered macrolide and ketolide antibiotics containing C12 modifications to a patient suffering from bacterial infections |
| 07/03/2003 | US20030125265 Administering to a cancer paient a compound (emodin, genistein) having anti-estrogen receptor activity and tyrosine kinase inhibitor activity to prevent esterogen receptor positive cancer cells |
| 07/03/2003 | US20030125264 Therapeutic flavonoid selected from flavones, flavonols, flavanones, isoflavanones, such as naringin, hesperidin, silybin, daidzin, genistin, genistein, quercetin and rutin. |
| 07/03/2003 | US20030125262 Methods and reagents for regulation of cellular responses in biological systems |
| 07/03/2003 | US20030125254 Method of inhibiting smooth muscle proliferation |
| 07/03/2003 | US20030125252 Administering to a vertebrate an effective osteogenesis stimulating amount of an RAR (retinoic acid receptor) antagonist to treat both metabolic or non-metabolic diseases; RAR antisense oligonucleotide |
| 07/03/2003 | US20030125248 Novel bone mineralization proteins, DNA, vectors expression systems |
| 07/03/2003 | US20030125246 Respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides known as respiratory system antigens useful for detecting cancer or cancer metastases of respiratory system tissues |
| 07/03/2003 | US20030125238 Hemoglobin-based oxygen carriers are prepared by reacting hemoglobin with oxidatively ring-opened polysaccharides such as hydroxyethyl starch or dextran, and storing the resultant conjugate under conditions which allow it to transform to a |
| 07/03/2003 | US20030125236 Phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the |
| 07/03/2003 | US20030125235 Treating a condition comprising administering a pharmaceutically effective amount of an inhibitor of the Tec family of protein tyrosine kinases (PTKs). The condition is typically associated with cytokine production, for treatment |
| 07/03/2003 | US20030125229 Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| 07/03/2003 | US20030125221 Method and composition for cleaning and disinfecting contact lenses |
| 07/03/2003 | US20030124723 Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 07/03/2003 | US20030124690 Novel compounds |
| 07/03/2003 | US20030124651 Hybridizing amplified HBV nucleic acids with an oligonucleotide probe in the presence of an enzyme that cleaves said probe |
| 07/03/2003 | US20030124644 Antibiotic production |
| 07/03/2003 | US20030124596 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 07/03/2003 | US20030124593 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 07/03/2003 | US20030124590 Carbohydrate response element binding protein and uses thereof |
| 07/03/2003 | US20030124558 Monitoring gestation in humans; in vitro fertilization and embryo transfer; progestins; immunohistochemistry |
| 07/03/2003 | US20030124534 Measuring expression of nucleotide sequences in cells |
| 07/03/2003 | US20030124529 Pregnancy-associated plasma protein-A2 (PAPP-A2) |
| 07/03/2003 | US20030124503 Sodium chloride, potassium chloride, glucose, insulin, calcium chloride, lidocaine; pyruvic acid or salt thereof; myocardial ischemia; protects in period of cardiac arrest |
| 07/03/2003 | US20030124222 Oilseed processing |
| 07/03/2003 | US20030124202 Formulations and methods for reducing skin irritation |
| 07/03/2003 | US20030124200 Sucralose, glucosamine and a beverage base, especially fruit juice; cartilage supplements include chondroitin, glucosamine, and hyaluronic acid |
| 07/03/2003 | US20030124196 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 07/03/2003 | US20030124193 Atomizing nozzles include a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas; spray drying at a commercial plant scale. |
| 07/03/2003 | US20030124191 Pharmaceutical or nutraceutical, surfactant, wetting agent and diluent; rapid release when contacted with mucosal surface |
| 07/03/2003 | US20030124190 Methods and compositions for treating pain of the mucous membrane |
| 07/03/2003 | US20030124188 Oral pulsed dose drug delivery system |
| 07/03/2003 | US20030124187 Having reduced weight compared to existing formulations; common intermediate granulate comprising a fixed ratio of amoxycillin and clavulanate, with differing ratios in the final formulation |
| 07/03/2003 | US20030124184 Liquiflash particles and an excipient mass; friability of less than 1%; need for conventional super disintegrant and having a friability of less than 1%; no need for conventional superdisintegrant |
| 07/03/2003 | US20030124181 Lipid carrier compositions with enhanced blood stability |
| 07/03/2003 | US20030124179 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 07/03/2003 | US20030124177 Compositions and methods for transdermal oxybutynin therapy |
| 07/03/2003 | US20030124176 Use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. |
| 07/03/2003 | US20030124174 Method for treating non-neuropathic pain |
| 07/03/2003 | US20030124170 Methods to reduce body fat |
| 07/03/2003 | US20030124161 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer |
| 07/03/2003 | US20030124159 Enhancing epidermal barrier development in skin |
| 07/03/2003 | US20030124157 Compositions containing aromatic aldehydes and their use in treatments |
| 07/03/2003 | US20030124151 Pamidronate solution |
| 07/03/2003 | US20030124150 Kit for reducing aching |
| 07/03/2003 | US20030124136 Immunotherapy for reversing immune suppression |
| 07/03/2003 | US20030124127 Targeting leukemia cells |
| 07/03/2003 | US20030124117 Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents |
| 07/03/2003 | US20030124116 Antibodies binding to polypeptides encoded by the genes |
| 07/03/2003 | US20030124111 Antimicrobial agent |
| 07/03/2003 | US20030124107 PAK5-related compositions and methods |
| 07/03/2003 | US20030124101 Sir2alpha-based therapeutic and prophylactic methods |
| 07/03/2003 | US20030124100 Includes an endothelial specific enhancer element; especially modifications of the PPE promoter, which enhance its expression in response to hypoxia and angiogenesis. |
| 07/03/2003 | US20030124097 Method to improve the safety of gene therapy |
| 07/03/2003 | US20030124092 IL-17 like molecules and uses thereoflike molecules and uses thereof |
| 07/03/2003 | US20030124088 Preparation for preventing bile acid diarrhea |
| 07/03/2003 | US20030124087 Prevents an adhesion between tissues at an operated legion and have various shapes, comprising sodium carboxymethyl cellulose and gellan gum |
| 07/03/2003 | US20030124086 Polymer conjugates of opioid antagonists |
| 07/03/2003 | US20030124083 Containing a humectant, a silicone lubricant, and sodium hyaluronate; avoids the harshness and drying associated with soap-based shave preparations |
| 07/03/2003 | US20030124075 Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer |
| 07/03/2003 | US20030124071 Containing 1,1,1-tris(2-methyl-4-hydroxy-5-tert-butylphenyl) butane |
| 07/03/2003 | US20030124063 Premeasured single unit dose; may be free of anti-microbial preservatives, such as benzalkonium chloride. |
| 07/03/2003 | US20030124058 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 07/03/2003 | US20030124055 Immobilization to polymer; antitumor agents, rheumatic diseases, autoimmune disease |
| 07/03/2003 | US20030124033 Method and apparatus for liposome production |
| 07/03/2003 | DE29522419U1 Multiple unit tabletted dosage form contg omeprazole - comprising enteric coated layered units of core material contg omeprazole compressed with excipients into tablets |
| 07/03/2003 | CA2849201A1 Adipose-derived cell processing unit |